Preliminary evidence of links between ayahuasca use and the corpus callosum.
ayahuasca
brain
corpus callosum
isthmus
neuro
psychedelics
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
07
2022
accepted:
05
10
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
epublish
Résumé
Recent research suggests that ayahuasca and its alkaloid-containing ingredients may be helpful in the treatment and prevention of certain movement and neurodegenerative disorders. However, such research is still in its infancy and more studies in normative samples seem necessary to explore effects of ayahuasca on clinically relevant brain structures, such as the corpus callosum. The purpose of the present study was to investigate links between ayahuasca use and callosal structure in a normative sample. Using structural imaging data from 22 ayahuasca users and 22 matched controls we compared the thickness of the corpus callosum between both groups at 100 equidistant points across the entire midsagittal surface. In addition, we investigated point-wise correlations between callosal thickness and the number of past ayahuasca sessions. The corpus callosum was significantly thicker within the isthmus in the ayahuasca group than in the control group. There was also a significant positive correlation between callosal thickness and the number of past ayahuasca sessions within the rostral body, albeit none of these effects survived corrections for multiple comparisons. No region was significantly thicker in the control than in the ayahuasca group, and no callosal region was negatively linked to ayahuasca use, even at uncorrected significance thresholds. This study provides preliminary evidence of links between ayahuasca use and the corpus callosum. However, future studies need to replicate these findings, preferably using larger sample sizes and ideally also utilizing longitudinal research designs, to draw any practical conclusion and offer implications for follow-up clinical research.
Sections du résumé
Background
UNASSIGNED
Recent research suggests that ayahuasca and its alkaloid-containing ingredients may be helpful in the treatment and prevention of certain movement and neurodegenerative disorders. However, such research is still in its infancy and more studies in normative samples seem necessary to explore effects of ayahuasca on clinically relevant brain structures, such as the corpus callosum.
Aims
UNASSIGNED
The purpose of the present study was to investigate links between ayahuasca use and callosal structure in a normative sample.
Methods
UNASSIGNED
Using structural imaging data from 22 ayahuasca users and 22 matched controls we compared the thickness of the corpus callosum between both groups at 100 equidistant points across the entire midsagittal surface. In addition, we investigated point-wise correlations between callosal thickness and the number of past ayahuasca sessions.
Results
UNASSIGNED
The corpus callosum was significantly thicker within the isthmus in the ayahuasca group than in the control group. There was also a significant positive correlation between callosal thickness and the number of past ayahuasca sessions within the rostral body, albeit none of these effects survived corrections for multiple comparisons. No region was significantly thicker in the control than in the ayahuasca group, and no callosal region was negatively linked to ayahuasca use, even at uncorrected significance thresholds.
Conclusion
UNASSIGNED
This study provides preliminary evidence of links between ayahuasca use and the corpus callosum. However, future studies need to replicate these findings, preferably using larger sample sizes and ideally also utilizing longitudinal research designs, to draw any practical conclusion and offer implications for follow-up clinical research.
Identifiants
pubmed: 36386967
doi: 10.3389/fpsyt.2022.1002455
pmc: PMC9643584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1002455Informations de copyright
Copyright © 2022 Simonsson, Bouso, Kurth, Araújo, Gaser, Riba and Luders.
Déclaration de conflit d'intérêts
OS is a co-founder of Eudelics AB. DA serves as a scientific and clinical advisor at Biomind Labs. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Aging Neurosci. 2017 Mar 22;9:68
pubmed: 28382000
Expert Opin Drug Saf. 2022 Jun;21(6):789-801
pubmed: 35301934
J Clin Psychopharmacol. 2016 Feb;36(1):77-81
pubmed: 26650973
J Psychiatr Res. 2015 Apr;63:10-9
pubmed: 25748753
Neuroimage. 2007 Oct 1;37(4):1457-64
pubmed: 17689267
Front Neurosci. 2018 Mar 20;12:185
pubmed: 29615862
J Neurol Sci. 2011 Aug 15;307(1-2):100-5
pubmed: 21621224
Neuroimage. 2011 Feb 1;54(3):1823-30
pubmed: 20932920
J Neurol. 2008 Dec;255(12):1904-9
pubmed: 19224318
Cortex. 1978 Jun;14(2):234-44
pubmed: 679704
Psychopharmacology (Berl). 2021 Feb;238(2):453-459
pubmed: 33118052
Front Neurosci. 2018 Aug 06;12:536
pubmed: 30127713
Front Pharmacol. 2019 Nov 19;10:1325
pubmed: 31798447
Neuroimage. 2014 Jan 1;84:820-4
pubmed: 24064068
Ann Neurol. 1998 Mar;43(3):360-9
pubmed: 9506553
Neurology. 2010 Nov 2;75(18):1645-52
pubmed: 21041787
J Pharmacol Sci. 2015 Jan;127(1):17-29
pubmed: 25704014
Neuroimage. 2006 Sep;32(3):989-94
pubmed: 16854598
Nat Rev Dis Primers. 2017 Oct 05;3:17071
pubmed: 28980624
Br J Pharmacol. 2021 Mar;178(6):1336-1352
pubmed: 32761823
Hum Brain Mapp. 2013 Sep;34(9):2259-65
pubmed: 22438280
Behav Brain Res. 2021 Feb 26;400:113003
pubmed: 33166569
Nat Rev Neurol. 2018 May;14(5):259-271
pubmed: 29569624
Exp Neurol. 2020 May;327:113245
pubmed: 32067950
Neuroimage. 2014 May 15;92:381-97
pubmed: 24530839
Mov Disord. 2010 Nov 15;25(15):2613-20
pubmed: 20623690
NPJ Parkinsons Dis. 2022 Aug 29;8(1):108
pubmed: 36038586
PeerJ. 2016 Dec 6;4:e2727
pubmed: 27957390
PLoS One. 2012;7(8):e42421
pubmed: 22905130
Brain Sci. 2018 Mar 16;8(3):
pubmed: 29547576
Braz J Psychiatry. 2020 Nov-Dec;42(6):646-656
pubmed: 32638916
J Neuroimmunol. 2020 Feb 21;342:577188
pubmed: 32179326
Amyotroph Lateral Scler Frontotemporal Degener. 2020 Aug;21(5-6):396-402
pubmed: 32106716
J Anat. 2006 Sep;209(3):311-20
pubmed: 16928200
Neuroreport. 2007 Feb 12;18(3):203-7
pubmed: 17314657
Transl Psychiatry. 2020 Sep 28;10(1):331
pubmed: 32989216
Biol Psychiatry. 2009 Jan 1;65(1):84-8
pubmed: 18842255
Psychol Med. 2019 Mar;49(4):655-663
pubmed: 29903051
Neurobiol Aging. 2007 Jun;28(6):955-63
pubmed: 16797787
Pharmaceuticals (Basel). 2020 Oct 23;13(11):
pubmed: 33114119
Science. 2009 Feb 13;323(5916):934-7
pubmed: 19213917
Neuroimage. 2006 Jul 15;31(4):1445-52
pubmed: 16563802
Mov Disord Clin Pract. 2015 Oct 06;3(1):19-26
pubmed: 30713897
Behav Brain Res. 2011 Sep 30;223(1):211-21
pubmed: 21530590
Cereb Cortex. 2012 Dec;22(12):2858-66
pubmed: 22223853
J Psychoactive Drugs. 2013 Apr-Jun;45(2):179-88
pubmed: 23909005
Brain Res. 1992 Dec 11;598(1-2):143-53
pubmed: 1486477
Neuropathology. 2013 Dec;33(6):591-9
pubmed: 23530811
Compr Psychiatry. 2016 Nov;71:95-105
pubmed: 27653781
Sci Rep. 2017 Jul 13;7(1):5309
pubmed: 28706205
Eur Neuropsychopharmacol. 2015 Apr;25(4):483-92
pubmed: 25637267